Historique
Rapport
Advocating for needle and syringe exchange programmes in prisons
Auteur(s) :
HRI (Harm Reduction International)
Année
2012
Page(s) :
4 p.
Sous-type de document :
Lettre d'information / Newsletter
Langue(s) :
Anglais
Éditeur(s) :
London : HRI (Harm Reduction International)
Collection :
Evidence and advocacy briefings series
Refs biblio. :
17
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
PRISON
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
ECHANGE DE SERINGUES
;
PROGRAMME
;
EFFICACITE
Thésaurus géographique
INTERNATIONAL
Résumé :
Imprisonment is a common experience for people who use drugs. Approximately 56-90% of people who use drugs will spend time in prisons for a variety of crimes including drug use, possession, trafficking and sale, as well as for acquisitive crimes committed to support drug use. In many countries around the world, the growth of prison populations and resulting overcrowding has been attributed to the police campaigns to arrest and prosecute drug offenders.
Evidence-based prison health programmes, including harm reduction interventions such as needle and syringe programmes (NSPs) and opioid substitution therapy (OST), significantly reduce drug-related harms among vulnerable populations. Since the early 1990s, an increasing number of countries have introduced these interventions to reduce HIV and HCV in prisons. iii However, the acceptance of harm reduction measures in places of detention has been difficult in most countries. This is often linked to the assumption on the part of policy-makers that such interventions are unsafe or inappropriate in closed environments.
This briefing provides answers to some of the most commonly encountered questions when advocating for harm reduction in prisons and places of detention.
Evidence-based prison health programmes, including harm reduction interventions such as needle and syringe programmes (NSPs) and opioid substitution therapy (OST), significantly reduce drug-related harms among vulnerable populations. Since the early 1990s, an increasing number of countries have introduced these interventions to reduce HIV and HCV in prisons. iii However, the acceptance of harm reduction measures in places of detention has been difficult in most countries. This is often linked to the assumption on the part of policy-makers that such interventions are unsafe or inappropriate in closed environments.
This briefing provides answers to some of the most commonly encountered questions when advocating for harm reduction in prisons and places of detention.